Skip to main content

Avidity’s stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone payments

Avidity's stock soared 30.5% early Tuesday on news of an expanded collaboration with Bristol Myers.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.